BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celgene Corporation (CELG)'s Abraxane Meets Main Goal in Melanoma Trial


10/3/2012 7:59:51 AM

(Thomson Reuters ONE via COMTEX) -- Celgene CELG moved closer today to securing another indication for its oncology drug, Abraxane, which is already approved as a second-line treatment for metastatic breast cancer. On Tuesday, Celgene announced that in a Phase III trial for metastatic melanoma, chemotherapy-naive patients treated with Abraxane showed a significant improvement in progression-free survival over those treated with dacarbazine, the only chemotherapy treatment currently approved for the skin cancer. If approved, analysts believe the added indication could become a billion dollar opportunity for Celgene, as melanoma is one of the most prevalent cancers in the U.S. and rates have been rising substantially in the last few decades.

Celgene acquired Abraxane in 2010 through the purchase of Abraxis BioScience, a $2.9B deal. Since its approval in 2005, Abraxane has had slow sales growth, but numbers are improving since Celgene took over. In 2011, the company's first full year with the drug, it reported Abraxane revenue of $386M, and already in the first and second quarters of this year the drug provided $104M and $110M respectively, putting it on pace for 2012 revenues of well over $400M. Regardless, a bigger opportunity may lie in future indications for the drug, which is in a Phase III trial for pancreatic cancer, and the FDA will vote on October 12th whether to approve Abraxane as an advanced non small-cell lung cancer (NSCLC) treatment; the pancreatic cancer data is expected late this year. Although these catalysts have driven CELG up substantially over the last three months, there is still some room to gain. CELG is approaching its 52-week high of $80.42 and will likely find resistance there until the NSCLC decision next week prompts a break-out in one direction or the other. Following the decision, investors are likely to again rally ahead of the pancreatic data later this year. CELG is up 1.5% in the afternoon.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com .

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: PropThink via Thomson Reuters ONE



Read at BioSpace.com

   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES